Prescribe Right Pharmaceutical Pipeline Update for August 21

Six updates we identified from over 200 Informational feeds from research presentations, study publication and news about drugs in development.
​

• Interim data from the first 16-weeks of a 36-week, 646 patient, Phase III trial, found that patients treated with fasinumab (from Teva, Regeneron) had an improvement in WOMAC scores compared to placebo in patients with osteoarthritis of the knee or hip. Patients treated with fastinumab every 4 weeks or 8 weeks had an improvement in pain (2.78, 2. 25) compared to placebo (1.59) and physical function was improved 2.57 to 2.10 compared to 1.37 with placebo.
• The FDA granted Motif Bio’s iclaprim a priority review on 8/14/18. Iclaprim Is given as a 2-hour infusion Q12 hr. In four Phase III skin infections trials the most common ADR for iclaprim were headache, nausea, vomiting, fatigue. It is the only DHFR- Inhibitor in our investigational knowledgebase. It’s indication is acute bacterial skin and skin structure infections and hospital acquired bacterial pneumonia.
• ViiV announced that in the 48-week, Phase III Atlas Trial, cabotegravir and rilpivirine,injected monthly was comparable in HIV viral suppression to a three drug oral regimen of 2 NRTIs plus a third drug. In a 96-week, 243 patient, Phase IIb trial, daily oral cabotegravir plus rilpivirine was comparable to efavirenz plus dual NRTIs in HIV viral suppression. Cabotegravir/rilpivirine is the only investigational entity within the INSTI/NNRT drug class in our knowledgebase.
• In a 431 patient, Phase III trial, patients treated with Medivation’s talazoparib had a PFS of 3 months longer than standard chemotherapy in patients with advanced breast cancer who carry the BRCA1 and BRCA2 mutations. 
• Gemphire Therapeutics has discontinued a trial evaluating use of gemcabene in the treatment of pediatric nonalcoholic fatty liver disease due to worsening of the disease in some patients
• In a 439-patient, Phase III trial, anlotinib (by Jiangsu Chiatai Qingjiang; Advenchen) improved OS versus placebo by 3.3 months and PFS by 4 months compared to placebo in patients with advanced NSCLC. There are seven other Tyrosine kinase inhibitor entities in our investigational knowledgebase.

You can access up-to-date information on all drugs in the late stages of development with the Prescribe Right Pharmaceutical Pipeline Tracker.